AR058955A1 - IMMUNGLOBULINS THAT JOIN INTERLEUQUINA 13 - Google Patents

IMMUNGLOBULINS THAT JOIN INTERLEUQUINA 13

Info

Publication number
AR058955A1
AR058955A1 ARP070100082A ARP070100082A AR058955A1 AR 058955 A1 AR058955 A1 AR 058955A1 AR P070100082 A ARP070100082 A AR P070100082A AR P070100082 A ARP070100082 A AR P070100082A AR 058955 A1 AR058955 A1 AR 058955A1
Authority
AR
Argentina
Prior art keywords
antibodies
hll
diseases
seq
amino acid
Prior art date
Application number
ARP070100082A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35997844&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058955(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR058955A1 publication Critical patent/AR058955A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpos que se unen específicamente a interleucina 13 humana (hlL-13). Los anticuerpos pueden utilizarse para el tratamiento de una variedad de enfermedades o trastornos sensibles a la modulacion de la interaccion entre hlL-13 y el receptor de IL-13 humana. Dichas enfermedades incluyen asma grave, dermatitis atopica, EPOC y diversas enfermedades fibroticas, composiciones farmacéuticas que comprenden dichos anticuerpos y procedimientos de fabricacion. Reivindicacion 1: Un anticuerpo o fragmento de union a antígeno del mismo que se une específicamente a hlL-13 y comprende CDRH3 como se define en la SEC N° ID 3 o variantes de la misma en las que uno o dos restos de aminoácidos en dicha CDRH3 difieren de los restos de aminoácidos en la correspondiente posicion en la SEC N° ID 3.Antibodies that specifically bind human interleukin 13 (hlL-13). Antibodies can be used for the treatment of a variety of diseases or disorders sensitive to modulation of the interaction between hlL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases, pharmaceutical compositions comprising said antibodies and manufacturing procedures. Claim 1: An antibody or antigen binding fragment thereof that specifically binds hlL-13 and comprises CDRH3 as defined in SEQ ID NO 3 or variants thereof in which one or two amino acid residues in said CDRH3 differ from amino acid residues in the corresponding position in SEQ ID NO 3.

ARP070100082A 2006-01-11 2007-01-09 IMMUNGLOBULINS THAT JOIN INTERLEUQUINA 13 AR058955A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0600488.1A GB0600488D0 (en) 2006-01-11 2006-01-11 Immunoglobulins

Publications (1)

Publication Number Publication Date
AR058955A1 true AR058955A1 (en) 2008-03-05

Family

ID=35997844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100082A AR058955A1 (en) 2006-01-11 2007-01-09 IMMUNGLOBULINS THAT JOIN INTERLEUQUINA 13

Country Status (18)

Country Link
EP (1) EP1976881A2 (en)
JP (1) JP2009523154A (en)
KR (1) KR20080113201A (en)
CN (1) CN101370829A (en)
AR (1) AR058955A1 (en)
AU (1) AU2007204372A1 (en)
BR (1) BRPI0706481A2 (en)
CA (1) CA2635972A1 (en)
CR (1) CR10161A (en)
EA (1) EA200801520A1 (en)
GB (1) GB0600488D0 (en)
IL (1) IL192207A0 (en)
MA (1) MA30156B1 (en)
NO (1) NO20082767L (en)
PE (1) PE20081185A1 (en)
TW (1) TW200736274A (en)
WO (1) WO2007080174A2 (en)
ZA (1) ZA200805526B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058104A1 (en) 2005-10-21 2008-01-23 Novartis Ag ORGANIC COMPOUNDS
EA017303B1 (en) 2006-05-25 2012-11-30 Глаксо Груп Лимитед Modified humanized anti-interleukin-18 antibodies and use thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
MX2011005541A (en) * 2008-11-26 2011-09-21 Glaxo Group Ltd Ligands that bind il-13.
EP2810652A3 (en) * 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2435481A1 (en) * 2009-05-28 2012-04-04 Glaxo Group Limited Il-13 binding protein
CA2775595A1 (en) 2009-10-20 2011-04-28 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
MX2013004212A (en) * 2010-10-15 2013-09-02 Medimmune Ltd Therapies for improving pulmonary function.
AR084342A1 (en) 2010-12-16 2013-05-08 Genentech Inc DIAGNOSIS AND TREATMENTS RELATED TO THE INHIBITION OF TH2
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
BR112016008694A2 (en) 2013-10-23 2017-10-03 Genentech Inc METHODS FOR PREDICTING THE REACTION OF PATIENTS WITH ASTHMA, FOR PREDICTING THE ABILITY TO REACT IN PATIENTS WITH ASTHMA, FOR IDENTIFYING PATIENTS WITH ASTHMA, FOR TREATMENT OF PATIENTS WITH ASTHMA AND FOR TREATMENT OF ASTHMA, USE OF A KIT AND KIT
CA2937556A1 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
US10066267B2 (en) 2014-04-11 2018-09-04 Novartis Ag Methods of selectively treating asthma using IL-13 antagonists
CN107430117A (en) 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 Detection and quantitative IL 13 method and the purposes in diagnosing and treating Th2 relevant diseases
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
EP3572426A4 (en) * 2017-01-23 2020-12-23 Toyo University Anti-epha2 antibody and immunological detection of epha2 using same
CN109776677B (en) * 2017-11-15 2023-11-03 尚华科创投资管理（江苏）有限公司 Humanized anti-IL-13 antibody and preparation method and application thereof
CN107909501B (en) * 2017-12-05 2020-12-01 创新先进技术有限公司 Smell and behavior association method, smell social method and device
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CA3133633A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496948A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
DK1711528T3 (en) * 2003-12-23 2012-08-20 Genentech Inc TREATMENT OF CANCER WITH UNTIL UNKNOWN ANTI-IL 13 MONOCLONAL ANTIBODIES
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
TW200736274A (en) 2007-10-01
GB0600488D0 (en) 2006-02-22
KR20080113201A (en) 2008-12-29
BRPI0706481A2 (en) 2011-03-29
JP2009523154A (en) 2009-06-18
EP1976881A2 (en) 2008-10-08
NO20082767L (en) 2008-10-06
IL192207A0 (en) 2008-12-29
WO2007080174A2 (en) 2007-07-19
ZA200805526B (en) 2009-10-28
AU2007204372A1 (en) 2007-07-19
PE20081185A1 (en) 2008-10-07
CA2635972A1 (en) 2007-07-19
EA200801520A1 (en) 2009-02-27
WO2007080174A3 (en) 2007-12-06
MA30156B1 (en) 2009-01-02
CN101370829A (en) 2009-02-18
CR10161A (en) 2008-11-26

Similar Documents

Publication Publication Date Title
AR058955A1 (en) IMMUNGLOBULINS THAT JOIN INTERLEUQUINA 13
CY1120414T1 (en) ANTIBODIES CONNECTED TO NO40 AND THEIR USES
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
AR049565A1 (en) ANTIBODIES OF UNION TO INTERLEUQUINA 13 HUMANA
EA200801842A1 (en) ANTIBODIES AGAINST BETA-AMILOIDHONE PEPTIDA
CO6430469A2 (en) HUMANIZED ANTIBODIES THAT JOIN CD19 AND ITS USES
NZ706377A (en) Il-6 antagonists and uses thereof
UA116772C2 (en) Cd47 antibodies and methods of use thereof
AR059604A1 (en) ANTIBODIES AGAINST IL-22 HUMAN AND USES FOR THE SAME
CA2813849C (en) Secukinumab for use in the treatment of ankylosing spondylitis
AR072897A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES GOING TO COMPLEMENT PROTEIN C5
BR112015014751A2 (en) human anti-tau antibodies
AR070346A1 (en) SPECIFIC ANTIBODY OF TIMICA STROMAL LYMPHOPYETINE RECEPTOR (TSLPR) AND USES IN ALLERGIC INFLAMMATORY AND INFLAMMATORY DISORDERS
EA201290570A1 (en) CONSTRUCTIONS CONNECTING WITH RON AND METHODS OF THEIR USE
NZ701444A (en) Antibodies to matrix metalloproteinase 9
CO6710903A2 (en) An antibody that specifically recognizes and binds with a phospho-epitope in the mammalian tau protein or in one of its fragments and a composition comprising the same
AR086516A1 (en) ANTI-PEPTIDE COMPOSITIONS RELATED TO THE CALCITONINE GENE AND ITS USE
RS52782B (en) High affinity human antibodies to human il-4 receptor
EA201370105A1 (en) HUMAN ANTIBODIES AGAINST THE HUMAN TNF-LIKAND-1A (TL1A)
BRPI0821168B8 (en) isolated antibody that binds to human IL-21, or a fragment thereof, uses of said antibody or fragment, and, hybridoma
EA201790757A1 (en) BONDING ANTIGEN CD27L PROTEINS
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
AR065312A1 (en) NEW ANTIBODIES
EA201491575A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
JP2016531546A5 (en)

Legal Events

Date Code Title Description
FB Suspension of granting procedure